Global Green, Inc. Signs Agreement with Merial for Evaluation of Salmonella Vaccine and License Option
TALLAHASSEE, Fla--(BUSINESS WIRE)--
Green, Inc. (OTCBB:GOGC) announces today the signing of an agreement
Ltd., the Animal Health Division of Sanofi,
to conduct an internal evaluation of Global Greens patented Salmogenics
vaccine technology. At the conclusion of the evaluation, Merial
has the first option to enter into a license agreement with Global Green
for the manufacture, distribution, and sale of the vaccine. Details of
the evaluation agreement are confidential.
is the only patented salmonella vaccine injected into the egg before the
chick is hatched. Salmogenics significantly reduces the presence of
salmonella in the chicken. Salmonella is an anaerobic bacteriathat
may enter the digestive tract of humans and other mammals in
contaminated food and cause abdominal cramps and pain, violent vomiting
and diarrheaor severe dehydration;it can alsoenter
the bloodstream which may lead to death.
The aim of the Salmogenics
vaccine is to improve the immune system, health and welfare of the 40
billion broiler chickens in the world and to provide a healthier source
of protein for humans in a more cost-effective manner. Salmogenics
testing has demonstrated a stronger immune system against salmonella as
well as increased weight gain and reduced mortality in poultry.
Salmogenics could lessen the need for use of antibiotics,an
essential benefit to both the poultry industry and, ultimately,
Mehran Ghazvini, DC, NMD, Chairman and CEO of Global Green, Inc.,
stated: This agreement with a world leader in the animal health sector,
such as Merial, further confirms the significance of our patented
Salmogenics vaccine technology. Our goal at Global Green, Inc. is to
produce vaccines that improve early immunity in chickens and other
animals, providing a safer and more cost-effective food source. Global
Green, Inc.s approach to animal health is to produce innovative,
environmentally-safe products and solutions which enhance the health,
well-being and performance of animals.
a Sanofi company, is a world-leading, innovation-driven animal health
company providing a comprehensive range of products to enhance the
health, well-being and performance of a wide range of animals. With a
total market share of more than 14 percent, Merial employs approximately
6,000 people and operates in more than 150 countries worldwide. Its 2012
sales were $2.8 billion. For more information, visit www.merial.com.
For more information about Sanofi, visit http://www.sanofi.us/l/us/en/index.jsp.
Green, Inc. is a green bio-pharmaceutical company committed to
identifying technology platforms and commercializing vaccines that
contain natural organisms that are not genetically modified, utilizing
pharmaceutical standards without the use of mercury. For more
information, visit www.globalgreeninc.com.
This press release may contain certain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
Investors are cautioned that such forward-looking statements involve
risks and uncertaintieswhich include, among others, the inherent
uncertainties associated with smaller reporting companies including
without limitation, other risks detailed from time to time in the
Company's periodic reports filed with the Securities and Exchange
Pam Lagano, firstname.lastname@example.org
Source: Global Green, Inc.